Articles written by Vandana Singh - Benzinga

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

New Home Sales Slide 13% As Builders Warn That Buyers Are Vanishing Again

U.S. new home sales fell sharply in May as high rates and economic uncertainty reduced affordability, driving buyer sentiment and builder confidence lower.

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.

BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering

BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position.

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30.

Why Is Bone Biologics Stock Surging On Friday?

Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regeneration patent portfolio.

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval.

Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.

Viatris Eye Drops Data Shows Promise For Blurred Near Vision

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.

Walgreens Crushes Sales Forecast, But Deeper Retail Troubles Lurk Beneath

Walgreens reported Q3 revenue of $38.99 billion and adjusted EPS of 38 cents, topping estimates as healthcare gains helped offset weaker retail sales.

Mars Just Got The Green Light For Its $36B Deal — But Europe Might Blow It Up

Mars' $36 billion acquisition of Kellanova clears FTC review, but EU raises concerns about pricing power and retailer negotiations in the EEA.

Shell Squashes BP Takeover Rumors, Hits Six-Month Ban

Shell said it has no plans to acquire BP, rejecting media reports and confirming no talks have occurred under the UK Takeover Code's Rule 2.8.

FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction

FDA highlights risks from recalled Medtronic devices tied to esophageal injuries and faulty cannulas, with serious health concerns and product warnings issued.

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences.

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.